US EditionPublished • loading... • Updated
Precigen, Inc. (PGEN) Stock Analysis: Unveiling A Potential 117.95% Upside In The Biotech Sector
Summary by DirectorsTalk Interviews
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Precigen, Inc. (PGEN) Stock Analysis: Unveiling A Potential 117.95% Upside In The Biotech Sector
Precigen, Inc. (NASDAQ: PGEN) is catching the attention of investors with its impressive potential upside of nearly 118%, according to analyst ratings. This biotechnology company, specializing in gene and cell therapies, is making strides in the healthcare sector with innovative approaches to combat diseases like cancer and autoimmune disorders. **Company Overview and Market Position** Headquartered in Germantown, Maryland, Precigen operates in …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
